1. Home
  2. GLUE vs MEI Comparison

GLUE vs MEI Comparison

Compare GLUE & MEI Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.

  • Machine Learning Prediction
  • ML Decision
  • GLUE
  • MEI
  • Stock Information
  • Founded
  • GLUE 2019
  • MEI 1946
  • Country
  • GLUE United States
  • MEI United States
  • Employees
  • GLUE N/A
  • MEI N/A
  • Industry
  • GLUE Biotechnology: Pharmaceutical Preparations
  • MEI Electrical Products
  • Sector
  • GLUE Health Care
  • MEI Technology
  • Exchange
  • GLUE Nasdaq
  • MEI Nasdaq
  • Market Cap
  • GLUE 351.2M
  • MEI 231.0M
  • IPO Year
  • GLUE 2021
  • MEI N/A
  • Fundamental
  • Price
  • GLUE $4.80
  • MEI $7.66
  • Analyst Decision
  • GLUE Buy
  • MEI Buy
  • Analyst Count
  • GLUE 2
  • MEI 2
  • Target Price
  • GLUE $13.50
  • MEI $10.50
  • AVG Volume (30 Days)
  • GLUE 369.2K
  • MEI 404.9K
  • Earning Date
  • GLUE 08-07-2025
  • MEI 09-03-2025
  • Dividend Yield
  • GLUE N/A
  • MEI 3.62%
  • EPS Growth
  • GLUE N/A
  • MEI N/A
  • EPS
  • GLUE 0.29
  • MEI N/A
  • Revenue
  • GLUE $177,986,000.00
  • MEI $1,048,100,000.00
  • Revenue This Year
  • GLUE $83.76
  • MEI N/A
  • Revenue Next Year
  • GLUE N/A
  • MEI $0.44
  • P/E Ratio
  • GLUE $16.32
  • MEI N/A
  • Revenue Growth
  • GLUE 2990.57
  • MEI N/A
  • 52 Week Low
  • GLUE $3.50
  • MEI $5.08
  • 52 Week High
  • GLUE $12.40
  • MEI $17.45
  • Technical
  • Relative Strength Index (RSI)
  • GLUE 51.69
  • MEI 63.37
  • Support Level
  • GLUE $4.54
  • MEI $6.52
  • Resistance Level
  • GLUE $4.93
  • MEI $7.83
  • Average True Range (ATR)
  • GLUE 0.21
  • MEI 0.28
  • MACD
  • GLUE 0.06
  • MEI 0.18
  • Stochastic Oscillator
  • GLUE 81.43
  • MEI 90.14

About GLUE Monte Rosa Therapeutics Inc.

Monte Rosa Therapeutics Inc is a biotechnology company that specializes in developing molecular glue degraders (MGDs), a class of small molecule drugs that leverage the body's natural protein destruction mechanisms to selectively degrade therapeutically-relevant proteins. Utilizing the QuEEN platform, the company employ artificial intelligence and proprietary experimental tools to identify target proteins for degradation by MGDs. With a diverse library of over 50,000 MGD molecules, their product candidate, MRT-2359, targets the translation termination factor protein GSPT1 for potential use in MYC-driven tumors. The company's focus lies in advancing its pipeline of MGDs, aiming to provide novel therapeutic modalities for various diseases.

About MEI Methode Electronics Inc.

Methode Electronics Inc supplier of custom-engineered solutions with sales, engineering, and manufacturing locations in North America, Europe, the Middle East, and Asia. It designs, engineers, and produces mechatronic products for Original Equipment Manufacturers (OEMs) utilizing a broad range of technologies for user interface, light-emitting diode (LED) lighting systems, power distribution, and sensor applications. The firm is organized into various business segments: Automotive, Industrial, Interface, and Medical. The Automotive segment, which generates maximum revenue, supplies electronic and electro-mechanical devices and related products to automobiles, including overhead and center consoles, hidden and ergonomic switches, insert molded components, LED-based lighting, and sensors.

Share on Social Networks: